ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,884Medicare Part D Prescriptions Filled, Including Refills

Rank: 234 out of 2456

$429K Total Retail Price of All Prescriptions

Rank: 305 out of 2456

396 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 396 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

6% of this provider’s 396 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 7,445 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
LISINOPRIL 454 425 1 1
LEVOTHYROXINE SODIUM 396 339 2 4
SIMVASTATIN 347 293 3 2
METOPROLOL TARTRATE 319 280 4 10
OMEPRAZOLE 283 242 5 3
AMLODIPINE BESYLATE 271 256 6 5
ATENOLOL 230 208 7 6
FUROSEMIDE 228 170 8 8
HYDROCHLOROTHIAZIDE 189 156 9 7
CITALOPRAM HBR 171 124 10 14
METFORMIN HCL 162 145 11 11
PRAVASTATIN SODIUM 161 154 12 15
LOSARTAN POTASSIUM 152 135 13 18
METOPROLOL SUCCINATE 131 129 14 13
SPIRONOLACTONE 130 130 15 73
LOVASTATIN 123 114 16 34
WARFARIN SODIUM 115 100 17 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 111 107 18 41
GABAPENTIN 96 86 19 16
AZITHROMYCIN 94 79 20 60
ALLOPURINOL 93 56 21 27
HYDROCODONE-ACETAMINOPHEN 91 42 S3 22 20
TRAZODONE HCL 90 64 23 17
DONEPEZIL HCL 80 80 24 23
TRAMADOL HCL 78 49 25 24
FLUOXETINE HCL 78 77 25 45
OXYCODONE HCL-ACETAMINOPHEN 76 31 S2 27 101
GLYBURIDE 76 71 R 27 40
PROAIR HFA 71 54 29 22
JANUVIA 71 55 29 81
FLUTICASONE PROPIONATE 70 55 31 30
SERTRALINE HCL 69 57 32 21
DIOVAN 67 67 33 26
ZOLPIDEM TARTRATE 65 54 34 28
DILTIAZEM 24HR ER 65 65 34 78
ENALAPRIL MALEATE 64 64 36 70
CIPROFLOXACIN HCL 56 46 37 87
PAROXETINE HCL 55 55 38 56
ATORVASTATIN CALCIUM 54 51 39 12
LOSARTAN-HYDROCHLOROTHIAZIDE 54 42 39 117
NAMENDA 54 54 39 42
PROPRANOLOL HCL 53 47 42 108
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 18, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.